Payment overview · 2025
General Payments
$66,496.41
164 reported records · 8 companies
Healthcare provider profile · identity verified
Anna E Kersey, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SAVANNAH, TN · NPI 1881954329
Verified facts
What the public records show
CMS Open Payments records show Anna E Kersey, PA received $66,496.41 in general payments during 2025 across 164 reported records.
ABBVIE INC. accounted for 90.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59,984.47 | 90.2% | 150 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $6,240.07 | 9.4% | 7 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.00 | 0.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.08 | 0.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.67 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.85 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.28 | 0.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.99 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,625.00 | 28 |
| Travel and Lodging | $10,293.96 | 45 |
| Honoraria | $5,500.00 | 2 |
| Food and Beverage | $4,077.45 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45,755.19 | 114 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32,079.16 | 78 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $6,240.07 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.08 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.67 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.14 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 184 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 40 |
| Omeprazole | Omeprazole | 115 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 113 | 32 |
| Lisinopril | Lisinopril | 100 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 21 |
| Simvastatin | Simvastatin | 73 | 29 |
| Alprazolam | Alprazolam | 70 | suppressed |
| Furosemide | Furosemide | 69 | 18 |
| Metformin Hcl | Metformin Hcl | 64 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 14 |
| Losartan Potassium | Losartan Potassium | 56 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 55 | 21 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 11 |
| Meloxicam | Meloxicam | 35 | 14 |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | 12 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | 11 |
| Allopurinol | Allopurinol | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Eliquis | Apixaban | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $66,496.41 · 164 records | ABBVIE INC. | BREZTRI, Kerendia, LEQVIO, NURTEC ODT, QULIPTA, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error